The Valley Desk

NCT00441155 · Interventional trial

Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib

Overall registry status Completed

Phase 1

Conditions Gastrointestinal Stromal Tumors

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov